ASCO Direct™ China 第29期丨Advanced Gastric Cancer Clinical Progress

Dr. Ruihua Xu, Sun Yat-sen University Cancer Center

Professor of Medical Oncology, President of Sun Yat-sen University Cancer Center, Director of State Key Laboratory of Oncology in South China, President of Chinese Society of Clinical Oncology (CSCO), Vice president of China Anti-cancer Association (CACA), Editor-in-Chief of Cancer Communications (IF 15.3)

Prof. Rui-hua Xu has been deeply engaged in the clinical work of medical oncology, and has made internationally advanced and innovative achievements in digestive system tumors, including early diagnosis, treatment and metastatic drug resistance:

1. He has pioneered a variety of treatment programs for advanced gastrointestinal tumors in the world. A new system for the whole course of colorectal cancer treatment has been developed, and the targeted therapy strategy for advanced gastric cancer under the guidance of molecular markers has been optimized. Many research results have been cited by the NCCN guidelines and have become a new international standard.

2. The application of ctDNA methylation technology and artificial intelligence-assisted endoscopy technology has improved the early diagnosis rate of digestive system tumors.

3. Breakthroughs have been made in the study of drug resistance in tumor metastasis, and the immunotherapy strategy guided by molecular markers has been innovated, which has significantly improved the efficacy and promoted the development of new drug clinical research in China.

The results from his research have been recorded into many international guidelines and classic monographs, which are popularized and applied all over the world. He has been selected as a highly cited scholar in China. Also, he is the editor-in-chief of the national postgraduate textbook "Oncology". Published 200 high-level papers as a correspondent or first author, and many articles were published in important international academic journals, such as "JAMA", "Nature Materials", "Nature Medicine", "Lancet Oncology", "Journal of Clinical Oncology", "JAMA Oncology", “Cancer Cell” etc.

Dr.George Fisher, Stanford University

Dr. George Fisher is a Professor of Medical Oncology at Stanford University where he specializes in gastrointestinal cancers. He received his PhD in Cancer Biology and did all of his medical training at Stanford.

Dr. Fisher is co-chair of the GI Committee for ECOG-ACRIN and serves on the NCI GI Steering Committee which is responsible for approving all randomized GI cancer trials within the National Cancer Trials Network (NCTN). His primary interest is in the design and conduct of therapeutic trials but he also collaborates with colleague in molecular biomarker and imaging research.

Dr. Kohei Shitara, National Cancer Center Hospital East

Dr Kohei Shitara is a Director of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. He received his medical degree from Tohoku University School of Medicine in 2002. Dr Shitara is an active member of ASCO and ESMO. He is working as one of the ESMO faculty member for Gastrointestinal Tumors, Upper digestive faculty group for the period 2021-2025. He is one of the organising members for Japanese gastric cancer treatment guidelines. Main research interests include development of new anti-cancer agents, optimal chemotherapy regimen for gastrointestinal cancer, and translational research. He is the primary investigator or study coordinator of several sponsor-initiated trials or investigator-initiated trials for gastric or colorectal cancer. He acts as one of steering committee members of several ongoing global studies in the field of GI cancers. He has reported more than 200 peer review publications which include approximately 100 articles as 1st author or corresponding author in major journals (NEJM, Lancet, Nature, etc.). He was recognised as one of a Highly Cited Researcher by Clarivate in 2022.

Dr. Xiaotian Zhang, Peking University Cancer Hospital

Dr. Huiyan Luo, Sun Yat-sen University Cancer Center

Luo’s primary research interests include clinical and translational research in GI medical oncology, especially in early diagnosis by liquid biopsy, artificial intelligence (AI)-assisted diagnosis system and developing prognostic and predictive markers in patients with GI cancerShe has published more than 20 papers in peer reviewed Journals like JAMA, Nature Materials, Lancet Oncology，Annals of Oncology, PNAS, Clinical Cancer research and presenting several abstracts to ASCO and ESMO meetings.

Dr. Junli Xue, Shanghai East Hospital, Tongji University

Secretary of National Health Commission Oncology Continuing Education Committee Secretary of China Pharmaceutical Innovation and Research Development Association (PhIRDA) anti-tumor drug clinical research Committee Standing committee member and Secretary of CSCO anti-cancer drug safety management committeeStanding committee member and secretary of CSCO Young committeeStanding committee member of CSCO immuno-oncology committeeStanding committee member of CSCO patients education committeeYouth editor of Editor of Won the highest honor for Young Medical Talents in Shanghai Health System, “Silver Snake Award”Selected in Shanghai Young medical talents training program, “New Star in Medical System”Selected as “Outstanding Academic Leader” of Pudong District

Dr. Xiaodong Zhu, Fudan University Shanghai Cancer Center

Member of China Anti-Cancer Association (CACA) Society of Cancer Targeted Therapy Vice chairman of Shanghai Anticancer Association (SACA) Hereditary Gastrointestinal Tumors Professionals CommitteeStanding committee member of SACA Tumor Biopharmacy CommitteeDirector of China Soong Ching Ling Foundation Cancer Medical and Industry-University-Research AllianceMember of China Medical Education Association (CMEA) Abdominal Tumor Professional CommitteeMember of SACA Gastrointestinal Cancer CommitteeMember of SACA Committee of Rehabilitation and Palliative Care (CRPC)Editor of

Dr. Li-Yuan Bai, China Medical University

Dr. Bai is currently the Director of the Division of Hematology and Oncology, Deputy Director of the Clinical Trial Center, and Professor of the Medicine college at the China Medical University. Dr. Bai received his medical degree from National Yang Ming Medical College, his master's degree from the Graduate institution of Medicine, and his doctoral degree from the Institute of the China Medical University and studied at the Ohio State University. Dr. Bai's clinical expertise is in the gastrointestinal tumors including stomach, pancreas and biliary tract, clinical trials of anti-cancer drugs and new drugs, and translational research of related tumors. Dr. Bai is currently a member of the IQVIA Asia Oncology Steering Committee (AOSC).